Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: A randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Respiratory Medicine

Volumn 4, Issue 6, 2016, Pages 445-453

  Behr, Jürgen ^a,b   Bendstrup, Elisabeth ^c   Crestani, Bruno ^d   Günther, Andreas ^e   Olschewski, Horst ^f   Sköld, C Magnus ^g   Wells, Athol ^h   Wuyts, Wim ⁱ   Koschel, Dirk ^j   Kreuter, Michael ^k   Wallaert, Benoît ^l   Lin, Chin Yu ^m   Beck, Jürgen ⁿ   Albera, Carlo ^o  

^a UNIVERSITY OF MUNICH   (Germany)

^b Member of the German Center for Lung Research   (Germany)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d BICHAT HOSPITAL   (France)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j Fachkrankenhaus Coswig   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m GENENTECH INC   (United States)

ⁿ InterMune International AG   (Switzerland)

^o UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; PIRFENIDONE; PLACEBO; EXPECTORANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ADULT; AGED; AORTA ANEURYSM; ARTICLE; ATRIAL FIBRILLATION; BACKACHE; BRONCHITIS; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; FOREARM FRACTURE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INTERVERTEBRAL DISK DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; OXYGEN SATURATION; OXYGEN THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WALKING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; EUROPE; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; VERY ELDERLY;

ACETYLCYSTEINE; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPE; EXPECTORANTS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PYRIDONES; TREATMENT OUTCOME;

EID: 84965062194     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30044-3     Document Type: Article

References (23)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
2. Kim DS, Collard HR, King TE Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006, 3:285-292.
3. Ley B, Collard HR, King TE Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:431-440.
4. Meltzer EB, Noble PW Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008, 3:8.
5. Strand MJ, Sprunger D, Cosgrove GP, et al. Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest 2014, 146:775-785.
6. Hutchinson J, Fogarty A, Hubbard R, McKeever T Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015, 46:795-806.
7. European public assessment report for Esbriet pirfenidone European Medicines Agency, (accessed Jan 12, 2016). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002154/human_med_001417.jsp&mid=WC0b01ac058001d124.
8. FDA approves Esbriet to treat idiopathic pulmonary fibrosis Food and Drug Administration, (accessed Jan 12, 2016). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm.
9. FDA approves Ofev to treat idiopathic pulmonary fibrosis Food and Drug Administration, (accessed Jan 12, 2016). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm.
10. OFEV (nintedanib) approved in the EU for the treatment of IPF Boehringer Ingelheim, (accessed April 28, 2016). https://www.boehringer-ingelheim.com/press-release/ofev-nintedanib-approved-eu-treatment-ipf.
11. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
12. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
13. Behr J, Demedts M, Buhl R, et al. Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res 2009, 10:101.
14. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229-2242.
15. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968-1977. for the Idiopathic Pulmonary Fibrosis Clinical Research Network.
16. Martinez FJ, de Andrade JA, Anstrom KJ, King TE, Raghu G Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2093-2101. for the Idiopathic Pulmonary Fibrosis Clinical Research Network.
17. Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B and the Response to N-acetylcysteine Among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2015, 192:1475-1482.
18. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015, 192:e3-19.
19. Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015, 46:186-196.
20. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014, 88:199-207.
21. Sakamoto S, Muramatsu Y, Satoh K, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology 2015, 20:445-452.
22. Poetker DM, Reh DD A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 2010, 43:753-768.
23. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011, 183:1231-1237.